← Back to Clinical Trials
Recruiting NCT07174661

NCT07174661 Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07174661
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Advanced Malignant Solid Neoplasm
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-09-02
Primary Completion 2027-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 39 Years
Study Type INTERVENTIONAL
Interventions
Advance Care PlanningEducational InterventionElectronic Health Record Review

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-09-02 with a primary completion date of 2027-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical trial studies whether educational tools work to improve early advance care planning (ACP) in adolescents and young adults (AYAs) with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and high-grade brain tumors. The incidence of AYA cancers is on the rise with approximately 90,000 new diagnoses yearly in the United States. Cancer remains the leading cause of disease-related death among AYAs, which could be due to patients having more advanced disease at presentation. It is recommended that AYAs begin ACP conversations at the start of treatment. ACP includes clarifying goals of care, discussions about end-of-life preferences, and completing a legal document that states the treatment or care a person wishes to receive or not receive if they become unable to make medical decisions (advance directive). The educational tools in this study include an early ACP educational video featuring AYAs with cancer and an ACP appointment geared for AYAs. Patients can access and watch the educational video at home prior to their scheduled ACP appointment. During the ACP appointment, a tailored ACP guide made specifically for AYAs is reviewed and questions regarding ACP are answered. This may help to introduce the importance of key ACP concepts, which may improve early ACP in AYAs with advanced solid tumors and high-grade brain tumors.

Eligibility Criteria

Inclusion Criteria: * Age 18-39 at initial cancer diagnosis * Patient \<18 years of age are not included in this pilot as Mayo Clinic in Arizona (MCA) does not treat pediatric patients * Recently diagnosed (defined as 12 months or less from initial diagnosis or advance stage relapse) with either a stage III/IV solid malignancy or high-grade brain tumor. This includes patients who have stage III/IV recurrence of previously stage I/II solid malignancy * Actively receiving primary oncologic care at Mayo Clinic Arizona * Able to read, understand, and speak English * Those who have completed prior advance directive documents are still eligible to participate. Exclusion Criteria: * Age \< 18 or \> 39 at initial cancer diagnosis * Diagnosed with stage I/II solid malignancy, low-grade brain tumor, or hematologic malignancy * Not receiving primary oncologic care at Mayo Clinic Arizona * Unable to read, understand, and speak English * Patients \> 12 months from initial diagnosis or advanced stage relapses, in survivorship or on hospice * No internet or computer/smart phone access

Contact & Investigator

Central Contact

Sey Oloyede

✉ oloyede.oluwaseyitan@mayo.edu

📞 507-538-6811

Principal Investigator

Allison C. Rosenthal, DO

PRINCIPAL INVESTIGATOR

Mayo Clinic

Frequently Asked Questions

Who can join the NCT07174661 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 39 Years, studying Advanced Malignant Solid Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07174661 currently recruiting?

Yes, NCT07174661 is actively recruiting participants. Contact the research team at oloyede.oluwaseyitan@mayo.edu for enrollment information.

Where is the NCT07174661 trial being conducted?

This trial is being conducted at Scottsdale, United States.

Who is sponsoring the NCT07174661 clinical trial?

NCT07174661 is sponsored by Mayo Clinic. The principal investigator is Allison C. Rosenthal, DO at Mayo Clinic. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology